PMID- 36619639
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - AIM platform: A new immunotherapy approach for viral diseases.
PG  - 1070529
LID - 10.3389/fmed.2022.1070529 [doi]
LID - 1070529
AB  - In addition to complications of acute diseases, chronic viral infections are 
      linked to both malignancies and autoimmune disorders. Lack of adequate treatment 
      options for Epstein-Barr virus (EBV), Human T-lymphotropic virus type 1 (HTLV-1), 
      and human papillomavirus (HPV) remains. The NexImmune Artificial Immune 
      Modulation (AIM) nanoparticle platform can be used to direct T cell responses by 
      mimicking the dendritic cell function. In one application, AIM nanoparticles are 
      used ex vivo to enrich and expand (E+E) rare populations of 
      multi-antigen-specific CD8(+) T cells for use of these cells as an AIM adoptive 
      cell therapy. This study has demonstrated using E+E CD8(+) T cells, the 
      functional relevance of targeting EBV, HTLV-1, and HPV. Expanded T cells consist 
      primarily of effector memory, central memory, and self-renewing stem-like memory 
      T cells directed at selected viral antigen peptides presented by the AIM 
      nanoparticle. T cells expanded against either EBV- or HPV-antigens were highly 
      polyfunctional and displayed substantial in vitro cytotoxic activity against cell 
      lines expressing the respective antigens. Our initial work was in the context of 
      exploring T cells expanded from healthy donors and restricted to human leukocyte 
      antigen (HLA)-A*02:01 serotype. AIM Adoptive Cell Therapies (ACT) are also being 
      developed for other HLA class I serotypes. AIM adoptive cell therapies of 
      autologous or allogeneic T cells specific to antigens associated with acute 
      myeloid leukemia and multiple myeloma are currently in the clinic. The utility 
      and flexibility of the AIM nanoparticle platform will be expanded as we advance 
      the second application, an AIM injectable off-the-shelf nanoparticle, which 
      targets multiple antigen-specific T cell populations to either activate, 
      tolerize, or destroy these targeted CD8(+) T cells directly in vivo, leaving 
      non-target cells alone. The AIM injectable platform offers the potential to 
      develop new multi-antigen specific therapies for treating infectious diseases, 
      cancer, and autoimmune diseases.
CI  - Copyright (c) 2022 Langan, Wang, Tidwell, Mitiku, Farrell, Johnson, Parks, Suarez, 
      Jain, Kim, Jones, Oelke and Zeldis.
FAU - Langan, David
AU  - Langan D
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Wang, Ruipeng
AU  - Wang R
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Tidwell, Keshanti
AU  - Tidwell K
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Mitiku, Selome
AU  - Mitiku S
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Farrell, Alison
AU  - Farrell A
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Johnson, Catrina
AU  - Johnson C
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Parks, Adam
AU  - Parks A
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Suarez, Lauren
AU  - Suarez L
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Jain, Shweta
AU  - Jain S
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Kim, Sojung
AU  - Kim S
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Jones, Kristi
AU  - Jones K
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Oelke, Mathias
AU  - Oelke M
AD  - NexImmune Inc., Gaithersburg, MD, United States.
FAU - Zeldis, Jerome
AU  - Zeldis J
AD  - NexImmune Inc., Gaithersburg, MD, United States.
LA  - eng
PT  - Journal Article
DEP - 20221223
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC9822776
OTO - NOTNLM
OT  - ACT
OT  - AIM
OT  - NexImmune
OT  - T cell
OT  - aAPC
OT  - immunotherapy
OT  - nanoparticle
OT  - viral
COIS- DL, RW, KT, SM, AF, CJ, AP, LS, SJ, SK, KJ, MO, and JZ were employees of 
      NexImmune, Inc.
EDAT- 2023/01/10 06:00
MHDA- 2023/01/10 06:01
PMCR- 2022/12/23
CRDT- 2023/01/09 03:55
PHST- 2022/10/15 00:00 [received]
PHST- 2022/12/07 00:00 [accepted]
PHST- 2023/01/09 03:55 [entrez]
PHST- 2023/01/10 06:00 [pubmed]
PHST- 2023/01/10 06:01 [medline]
PHST- 2022/12/23 00:00 [pmc-release]
AID - 10.3389/fmed.2022.1070529 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Dec 23;9:1070529. doi: 10.3389/fmed.2022.1070529. 
      eCollection 2022.